Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Author(s): Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, et al.


Objective:To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome).

Methods:We conducted a multicenter, randomized, double-blind, placebo-controlled trial. Patients with a first clinical demyelinating event and at least two clinically silent brain MRI lesions were randomized to interferon beta-1b (IFNB-1b) 250 mug subcutaneously (SC) every other day (EOD) (n = 292) or placebo (n = 176), until clinically definite MS (CDMS) was diagnosed or they had been followed for 24 months.

Results:After 2 years, 45% of placebo patients had converted to CDMS (Kaplan-Meier estimate; primary outcome measure) and 85% fulfilled the McDonald criteria (co-primary outcome measure). Overall interferon beta-1b delayed the time to diagnosis of CDMS (p < 0.0001) and McDonald MS (p < 0.00001). Hazard ratios (95% CI) were 0.50 (0.36 to 0.70) for CDMS and 0.54 (0.43 to 0.67) for McDonald MS favoring treatment with IFNB-1b. Treatment was well tolerated, as indicated by the low rate of patients dropping out of the study before CDMS was reached (6.6% overall, 7.2% in the IFNB-1b group).

Conclusions:Interferon beta-1b 250 mug subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.

Similar Articles

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis

Author(s): Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM et al.

Quality of life in multiple sclerosis patients in Spain

Author(s): Chang CH, Cella D, Fernández O, Luque G, de Castro P, et al.

[The Spanish version of EuroQol: a description and its applications

Author(s): Badia X, Roset M, Montserrat S, Herdman M, Segura A

Autonomous regulation and long-term medication adherence in adult outpatients

Author(s): Williams GC, Rodin GC, Ryan RM, Grolnick WS, Deci EL

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

Author(s): Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, et al.